# MSC for Treatment of Interstitial Lung Disease After Allo-HSCT

> **NCT02543073** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Lung Diseases, Interstitial
- Hematopoietic Stem Cell Transplantation
- Bronchiolitis Obliterans

## Interventions

- **BIOLOGICAL:** MSCs
- **DRUG:** AZM
- **DRUG:** Glucocorticoid

## Key facts

- **NCT ID:** NCT02543073
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2017-12
- **Final completion:** 2018-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02543073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02543073, "MSC for Treatment of Interstitial Lung Disease After Allo-HSCT". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02543073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*